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INTRODUCTION 
Cancer is one of the major causes of mortality. The 
worldwide incidence of cancer continues to increase. 
Cancer is known to develop via a multistep carcinogenesis 
process entailing numerous cellular physiological systems 
such as cell signalling and apoptosis, making it a highly 
incomprehensible and complex disease. The most common 
cancer treatments are limited to chemotherapy, radiation, 
and surgery. 
Greater targeting selectivity and better delivery efficiency 
are the 2 major goals in the development of therapeutic 
agents or imaging contrast formulations. At present, non-
invasive imaging approaches, including x-ray–based 
computer-assisted tomography (CT), positron emission 
tomography (PET), single-photon emission tomography, 
and magnetic resonance imaging (MRI), are used as 
important tools for detection of human cancer.
1-2 
The development of tumour-targeted contrast agents based 
on a nanoparticle formulation may offer enhanced 
sensitivity and specificity for in vivo tumour imaging 
using currently available clinical imaging modalities.
3
 
 Nanotechnology refers to the interactions of cellular and 
molecular components and engineered materials—
typically clusters of atoms, molecules, and molecular 
fragments—at the most elemental level of biology.  By 
creating nanometres-scale structures, it is possible to 
control fundamental characteristics of a material, including 
its melting point, magnetic properties, and even color, 
without changing the material’s chemical composition.  
The theme of nanotechnology is the control of material on 
a scale of 1 to 100 nanometres and fabricates the devices 
on this scale of length. On nano scale, there is vastly 
increase in ratio of surface area to volume. Due to this, 
materials at nano scale show very different properties 
compared to what they exhibit on a micro scale, enabling 
unique applications. For instance, 
• Opaque substances become transparent (copper), 
• Inert material becomes catalysts (platinum), 
• Stable material turn combustible (aluminium), 
• Solids turn into liquids at room temperature (gold), 
• Insulator becomes conductors (silicon).4 
 By applying a vast and diverse array of nanoparticles, 
whose design derives from the engineering, chemistry, and 
medicine fields, to molecular imaging and targeted 
therapy, cancer nanotechnology promises solutions to 
several of the current obstacles facing cancer therapies. 
Nanotechnology is a ―disruptive technology‖ which drives 
a new generation of cancer preventive, diagnostic, and 
therapeutic products, resulting in dramatically improved 
cancer outcomes. Nanoparticle drug delivery using 
biodegradable polymers is expected to provide a more 
efficient way to overcome some of these problems. 
 
Nanoparticles: 
Nanoparticles have a mesoscopic size range of 5 to 200 
nm, allowing their unique interaction with biological 
systems at the molecular level. As a result of their material 
composition, nanoparticles are capable of self-assembly 
and maintaining stability and specificity, which are crucial 
to drug encapsulation and biocompatibility. Recent 
progress in cancer nanotechnology raises exciting 
opportunities for personalized oncology in which diagnosis 
and treatment are based on the molecular profiles of 
individual patients.  
In this, we will address first the types and characteristics of 
nanoparticles; second, how nanoparticles can be used as 
drug delivery systems and imaging devices to increase the 
efficacy per dose of therapeutic or imaging contrast agents; 
and last, how nanoparticles will be further developed to 
improve their functionality in cancer treatment and 
imaging.
5-7
 
ABSTRACT 
Cancer is caused by damage of genes which control the growth and division of cells. Detection/diagnose/treatment is possible 
by confirming the growth of the cells and treated by rectifying the damaging mechanism of the genes or by stopping the blood 
supply to the cells or by destroying it. The application of nanotechnology for cancer therapy has received considerable 
attention in recent years. Cancer nanotechnology (an interdisciplinary area of research in science, engineering and medicine) is 
an upcoming field with extensive applications. Recent developments in nanotechnology have provided researchers with new 
tools for cancer imaging and treatment. This technology has enabled the development of nanoscale devices that can be 
conjugated with several functional molecules simultaneously, including tumour-specific ligands, antibodies, anticancer drugs, 
and imaging probes. Since these nanodevices are 100 to 1,000-fold smaller than cancer cells, they can be easily transferred 
through leaky blood vessels and interact with targeted tumour-specific proteins both on the surface of and inside cancer cells. 
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Nanocarriers can offer many advantages over free drugs. 
They: 
• protect the drug from premature degradation; 
• prevent drugs from prematurely interacting with the 
biological environment; 
• enhance absorption of the drugs into a selected tissue 
(For example, solid tumour); 
• control the pharmacokinetic and drug tissue distribution 
profile; 
• improve intracellular penetration. 
 
 
                                                                                                             
 
 
 
 
 
 
                  
Figure 1: Schematics diagram showing nanotechnology applications in cancer 
NANOPARTICLES FOR TUMOUR TARGETING 
AND DELIVERY: 
Types of Nanoparticles as Drug Delivery Systems: 
1.  Liposomes 
2. Polymeric Nanoparticles (Nano spheres and Nano 
capsules) 
3.  Solid lipid particles 
4.  Nano crystals 
5.  Polymer Therapeutics such as dendrimers, fullerenes. 
6.  Inorganic Nanoparticles (e.g. Gold & Magnetic Nano 
particles) 
Liposomes and Other Lipid-based Nanoparticles 
 Liposomes are the small vesicle of spherical shape that 
can be produced from cholesterols, non toxic surfactants, 
sphingolipids, glycolipids, long chain fatty acids and even 
membrane proteins. Liposomes are the most studied 
formulation of nanoparticle for drug delivery. Several 
types of anticancer drugs have been developed as lipid-
based systems by using a variety of preparation methods. 
Liposomal formulations have shown an ability to improve 
the pharmacokinetics and pharmacodynamics of associated 
drugs. Liposome-based formulations of several anticancer 
agents (Stealth liposomal doxorubicin [Doxil], liposomal 
doxorubicin [Myocet], and liposomal daunorubicin 
[DaunoXome]) have been approved for the treatment of 
metastatic breast cancer and Kaposi's sarcoma. 
[8-14] 
 
Figure 2: Structure of Lipid-based Nanoparticle 
First generation liposomes have an unmodified 
phospholipid surface that can attract plasma proteins, 
which in turn trigger recognition and uptake of the 
liposomes by the mononuclear phagocytic system (MPS), 
which is synonymous with the reticuloendothelial system, 
resulting in their rapid clearance from the circulation. The 
Surface-modified liposomes (Stealth) have hydrophilic 
carbohydrates or polymers, which usually are lipid 
derivatives of polyethylene glycol (PEG) grafted to the 
liposome surface. While this surface modification has 
solved the problem of fast clearance from the circulation, 
yielding liposomes with a significantly increased half-life 
in the blood, the challenge remains to attain preferential 
accumulation of liposomes in tumour tissues. One strategy 
to achieve tumour-specific targeting is to conjugate a 
targeting moiety on the outer surface of the lipid bilayer of 
the liposome that selectively delivers drug to the desired 
site of action. For example, an immunoliposome has 
antibodies or antibody fragments conjugated on its outer 
surface, usually at the terminus of PEG. Several studies 
have documented improved therapeutic efficacy of 
immunoliposomes targeted to internalizing antigens or 
receptors compared with that of nontargeted liposomes.
15-20
 
Polymeric Nanoparticles 
  To reach the targeted tumour tissue, nanoparticles must 
be able to stay in the bloodstream for considerable lengths 
of time without being eliminated. Nanoparticles with no 
surface modification are usually caught by the MPS, 
primarily the liver and spleen, during circulation, 
depending on their size and surface characteristics.
21
 
To overcome this problem, nanoparticles can be coated 
with hydrophilic polymers. Coating can efficiently protect 
nanoparticles from capture by macrophages.
22-24 
The 
increased hydration also helps nanoparticles to be more 
water soluble and less sensitive to enzymatic degradation, 
therefore enhancing biocompatibility.
25-26
  Recently, a 
nanoparticle formulation of paclitaxel bound to albumin 
(Abraxane or ABI-007) was approved for the treatment of 
metastatic breast cancer. In a Phase III clinical trial, ABI-
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007 showed greater therapeutic efficacy and increased 
response compared with free paclitaxel. Currently, more 
than 10 formulations of anticancer polymeric nanoparticles 
have entered clinical development, including paclitaxel 
poliglumex (Xyotax) N-(2-hydroxypropyl) 
methacrylamide (HPMA) copolymer-camptothecin (MAG-
CPT) and HPMA-DOX (PK1)
27-29
 
Multifunctional nanoparticles for tumour imaging 
Tumour imaging plays a key role in clinical oncology, 
with radiological examinations able to detect solid 
tumours, determine recurrence, and monitor therapeutic 
responses. Conventional tumour  imaging approaches such 
as CT and MRI focus mainly on delineating morphological 
features of the tumour, tissue, and organs, such as the 
anatomic location, extent, and size of the tumour, at 
various levels of spatial resolution and contrast.  
 Recent advances have stimulated the emergence of the 
new field of ―molecular imaging,‖ which focuses on 
visualizing or imaging biological events and processes in 
living systems, including patients. 
30 
 Current molecular imaging approaches, including PET, 
single-photon emission tomography, and optical imaging 
including fluorescence-mediated tomography and near-
infrared fluorescence reflectance (NIRF) imaging, have 
shown a high sensitivity in non-invasive tumour imaging. 
31-33
 
A commonly used PET imaging probe,  F-labeled 
fluorodeoxyglucose (FDG), can only localize tumours by 
identifying cells in the body that have increased glucose 
uptake and metabolism, allowing for the detection of those 
tumours. However, it is not suitable for tumour types with 
a low glucose uptake. It is well recognized that the 
development of novel approaches for early cancer 
detection and effective therapy will significantly contribute 
to the improvement of patient survival. The development 
of nanoparticles as imaging contrast agents also makes it 
possible for the production of multifunctional 
nanoparticles with the capacity of targeted tumour imaging 
and delivery of therapeutic agents. In comparison with 
radioactive probes (i.e., F-labeled FDG) used for PET 
imaging, nanoparticles have both greater surface areas and 
more functional groups that can be linked with multiple 
diagnostic and therapeutic agents.
34-38
  
Advances in nanotechnology have shown the promise of 
nanoparticles for tumour-targeted drug delivery and non-
invasive tumour imaging. With unique pharmacokinetics, 
nanoparticles with sizes between 10 to 100 nm have a 
prolonged circulation time since they are usually not taken 
up by the MPS within the liver or excreted by the kidney, 
common limitations to the delivery of small molecular 
imaging agents or drugs. Such nanoparticles can navigate 
the vasculature and cross barriers through small capillaries 
into tumour cells.  Nanoparticles of specific sizes can be 
synthesized under controlled conditions to obtain the 
desired optical and magnetic properties and levels of 
therapeutic agents attached to the particles. These 
properties offer the opportunity to design ―smart‖ 
nanoparticles, including target-specific contrast agents, 
multimodality imaging probes, or even multifunctional 
reagents for simultaneous imaging and treatment. 
39-43
 
Quantum Dot Nanoparticles 
 Semiconductor quantum dots (QDs) are nanometre-scale, 
light-emitting particles with unique optical and electronic 
properties such as size-tunable light emission, improved 
signal brightness, enhanced stability of the fluorescent 
signal, and the ability to simultaneously excite multiple 
fluorescent colors.
[44]  
 
Figure 4: Structure of Quantum Dot Nanoparticles 
These properties are most promising for improving the 
sensitivity of molecular imaging and quantitative cellular 
analysis by 1 to 2 orders of magnitude.
45
 Recently QDs 
producing NIRF signals have been developed. NIRF light 
penetrates much more deeply into tissues compared with 
visible fluorescence and allows for the detection of signals 
inside animals, as compared with visible fluorescent 
signals, which can only pass through several millimetres in 
the tissues. A major advantage of NIRF QDs is that their 
emission is well beyond the spectral range of the 
fluorescence signal produced by blood and tissues 
(autofluorscence), resulting in imaging with a high signal-
to-background ratio.
46 
Magnetic Iron Oxide Nanoparticles 
 Super paramagnetic iron oxide (SPIO) or iron oxide (IO) 
nanoparticles are becoming increasingly attractive as the 
precursor for the development of a target-specific MRI 
contrast agent. IO nanoparticles have unique paramagnetic 
properties, which generate significant susceptibility effects 
resulting in strong T2 and T*2 contrast, as well as T1 
effects at very low concentrations.
47-50
 
In addition to the previously described unique properties 
and advantages of nanomaterials, IO nanoparticles have a 
long blood-retention time and are generally biodegradable 
and considered to have low toxicity. Several forms of IO 
nanoparticles have been used in clinical settings and have 
proven to be safe for human use. Some recent studies have 
demonstrated that IO nanoparticles can be internalized by 
various cell lines, which allows for magnetic labelling of 
the targeted cells. These features give IO nanoparticles 
great advantages for in vivo tumour imaging and drug 
delivery compared with other types of nanoparticles
. 51-56
 
Recent efforts also focus on the development of 
ultrasensitive magnetic nanoprobes for tumour imaging. 
Using magnetism-engineered iron oxide nanoprobes that 
are conjugated with HER-2 antibodies, Lee et al showed 
an enhanced sensitivity of MRI for the detection of HER-2 
expressing cancer in an animal model compared with that 
of commonly used SPIO probes. This new generation of 
magnetic nanoparticles should provide us with a powerful 
contrast agent for cancer detection.
57
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Figure 2: Structure of a Superparamagnetic Iron Oxide 
(SPIO) Poly Acryl amide Magnetic (PAM) 
8. Dendrimers 
Dendrimers are a unique group of nanoparticles that are 
highly suitable for effective delivery of drugs, particularly 
for cancer treatment.  Dendrimers can be synthesized by 
controlled, repeated polymerization reactions to engineer a 
desired shape and size.  The main  advantage of 
dendrimers  is their exclusive  branching  point that is 
available for conjugation  to  multiple  entities ,  including 
targeting proteins, treatment moieties, and even apoptosis 
factor ligands .  Chemotherapy drugs, when incorporated 
into the core of the dendrimer, do not    affect healthy cells. 
Antibody-dendrimer conjugates have been used for 
radiolabeling with minimal loss of immunoreactivity. 
Some research shows that the anti-PSMA antibody J591 
when conjugated to a dendrimer containing a 
fluorochrome, can be used for targeting prostate cancer 
and has potential as an efficient delivery system for 
therapeutics and imaging agents  The  dendrimer  can be 
engineered  so  that when  it  gets  into  the target tumor 
cell,  it can change its conformation,  allowing the 
incorporated moiety to  be released  to the tumor site,  
efficiently  suppressing  tumor growth.  The size, 
tenability, and multifunctional capability to enhance 
multiple drug interactions to deliver a chemotherapeutic 
agent to the specific tumor site make dendrimers an 
excellent nano-carrier for tumor targeting and therapy.
58
 
Gold Nanoshells 
Gold nanoshells are useful in detecting tumors and 
metastasis in many solid tumors.  The main advantage of 
the gold is its potential for cancer detection and treatment 
of cancers using near-infrared light.  In a study where 
silica/gold nanoshells were used to treat breast cancer in 
vivo, the nanoshells were injected into the tumor site and 
irradiated with 820 nm, light pulses.  The tumor site 
increased  in  temperature when irradiated with light,  and 
thus  this system  had  the  ability  to destroy the tumor 
cells without causing  any harm to the surrounding,  
normal cells. In  another  step forward,  gold  nanoshells  
were  conjugated  with ligands  for specific accumulation 
in  oral squamous carcinoma cell lines (HSC 313 and HOC 
3 Clone 8) .  Furthermore, these kinds of nanoshells have 
been used for targeted delivery and therapy of many 
cancers, including breast and prostate cancers.
 59 
Carbon Nanotubes 
Another type of nano device for biomarker detection is 
carbon nanotubes (CNTs).Using single-walled carbon 
nanotubes as high-resolution atomic force microscopy 
(AFM) tips, Woolley et al.  Showed that specific 
sequences of kilo base-size DNA can be selectively 
detected from single-base mismatch sequences. 
Specifically, target DNA fragments were first hybridized 
with labeled (for instance, strepavidin-labeled) 
oligonucleotides, and then AFM was used to directly 
detect the presence and special location of the labels. This 
technique enabled the simple and direct detection of 
specific heliotypes that code for genetic disorders such as 
cancer. CNT-modified electrodes can amplify the 
electrochemical signal of guanuine bases, which has been 
used for label-free electrochemical detection of DNA at 
nanomolar concentrations. More recent work has utilized 
CNTs as nanoscale carriers for imaging and therapeutic 
agent delivery.
60 
Nanowires 
Nanowires are available in metallic, semiconductor, 
magnetic, oxide, and polymer compositions and are 
promising as ultra small chemical and biological sensors. 
Functionalized nanowires are coated with capture ligands 
such as antibodies. For personal use only.oligonucleotides. 
In the presence of target molecules, the specific binding 
between target molecule and capture molecule generates 
an immediate conductivity change within the nanowire that 
can be measured.
61 
Implications and future directions 
 Cancer is known to develop via a multistep carcinogenesis 
process and to progress using several complex survival 
mechanisms, such as self-sufficiency in growth signalling, 
insensitivity to growth inhibitory signals, evasion of 
apoptosis, limitless replicative potential, sustained 
angiogenesis, and tumour invasion and metastasis.
62
 
Molecularly targeted therapy is a recent introduction 
acknowledging our increased understanding of these 
cancer behaviours at the molecular level. Success of 
targeted therapies depends on expression of the targeted 
molecules, which can also serve as cancer-specific 
biomarkers. 
63
 
 The development of multifunctional nanoparticles may 
contribute significantly to the realization of individualized 
therapy for cancer. Ideally, for constructing 
multifunctional nanoparticles, an appropriate combination 
of agents (therapeutic agent and targeting moiety) will be 
chosen based on accurate biological information within the 
tumour (molecular biomarker profiling of the patient) with 
imaging material attached on the nanoparticle surface. 
Nanoparticles may eventually be capable of detecting 
malignant cells (active-targeting moiety), pinpointing and 
visualizing their location in the body (real-time in vivo 
imaging), killing the cancer cells with minimal side effects 
by sparing normal cells (active targeting and controlled 
drug-releasing system), and reporting back that their 
payload has accomplished its mission (monitoring 
treatment effects in real time).
64 
 Detection and diagnosis through nanotechnology  
Another important issue to be addressed is cancer 
diagnosis through nanotechnology. In order to provide 
early and thus more effective cancer treatment, early 
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detection of the disease is crucial. Two approaches to 
cancer detection may be envisioned and they include 
• In vitro (laboratory-based) diagnostics 
• In vivo diagnostics. 
In vitro (laboratory-based) diagnostics 
Laboratory-based (in vitro) nanotechnology methods are 
based on the concept of computer chips. For example, with 
the use of some recent discoveries in nanoarrays, we can 
now detect multiple biomolecular markers at very low 
concentrations in various biological fluids. There are 
currently two equally effective nanoarray methods.  
The first method involves nanowires (Figure 20) connected 
to a high-sensitivity electronic ammeter. Each nanowire is 
designed to be a good binding site for a specific bio 
molecule. The bio fluid under study is passed through a 
channel where it is allowed to come into direct contact 
with the wire array. The conductance of the wires changes 
as the molecules bind, and detection is made possible by 
measuring the conductance in real time. 
65
 
In-vivo diagnostics.  
The second method involves a nanoarray of Atomic Force 
Microscope (AFM) cantilevers which are equipped with 
antibodies specific to selected molecules. The array is 
submerged in a biofluid where the molecules that are 
present are allowed to bind to the antibodies. As they bind, 
they cause the levers to deflect, and the deflection is 
measured by a combination of a highly focused laser beam 
and sensitive photo detectors, with a technique similar to 
that used in AFM. Both methods can yield data that are 
highly accurate, even with concentrations in the range of 
parts per million. Some promising in vivo techniques are 
currently under development. One method is to use 
nanoarrays similar to those described above. However, due 
to conditions that are much more adverse in a living 
patient, significantly higher concentrations of the desired 
molecules are necessary for accurate detection. Another 
method is to implant biosensors directly into the patient 
and to have them relay gathered information to an external 
data collector. The major problem with these methods that 
still remains unresolved is bio fouling or the nonspecific 
adoption of serum proteins to the sensors.
66
 Since serum 
proteins are present in healthy as well as malignant 
environments, the accuracy of the measurements can be 
greatly impaired. This problem has been in the way of 
effective in vivo detection for quite some time. 
CONCLUSION  
Cancer nanotechnology field has the potential to better 
monitor therapeutic efficacy, provide novel methods for 
detecting and profiling early stage cancers, and for 
enabling surgeons to delineate tumour margins and 
sentinel lymph nodes. Nanomaterials have unique features 
that are attractive, and can be applied to bio sensing. An 
important aspect of cancer treatment is its early detection. 
There have been significant improvements largely due to 
breakthroughs, both, in the bottom-up and in the top-down 
nanotechnology. A nanoparticle holds new promise as 
means for earlier detection and better treatment of cancer. 
Imagine a future where nanoparticles can help detect 
cancer before it even has a chance to manifest, and 
selectively destroy cancer cells while leaving the normal 
cells unharmed. Cancer, in such a circumstance, could 
become a highly manageable condition. However, despite 
our current research there is much we still do not 
understand. Nanoparticles offer a new avenue to tackle 
these challenges. More research is needed in this 
promising and dynamic field of cancer therapeutics. 
Developments in such areas as in nanoarrays, nanosensors, 
liposomes, monoclonal antibodies, improved nanoparticles 
(dendrimers, diamondoids, gold-based nanoparticles, 
magnetic nanoparticles, and quantum dots) and 
nanoelectronics are making early detection, prevention and 
treatment with a high degree of accuracy and ease 
possible. Also other recent discoveries and inventions in 
nanotechnology are suggesting that a safe and effective 
cure for cancer is just around the corner. Of course the 
hope is to turn cancer into a manageable ailment that we 
can treat and we can live with. 
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